You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGFR TKI

Showing 1 - 25 of 801
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma Trial in Shanghai (Camrelizumab Combined With Apatinib)

Recruiting
  • PD-1 Immunotherapy
  • +3 more
  • Camrelizumab Combined With Apatinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 1, 2022

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Clear Cell Metastatic Renal Cell Carcinoma Trial in France (Nivolumab, Ipilimumab, Pazopanib)

Completed
  • Clear Cell Metastatic Renal Cell Carcinoma
  • Bordeaux, France
  • +15 more
Apr 22, 2021

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Renal Cell Carcinoma Who Received First-Line Sunitinib

Completed
Has Results
  • Metastatic Renal Cell Carcinoma
  • Calgary, Alberta, Canada
    University of Calgary
Feb 19, 2021

Carcinoma, Renal Cell Trial in Worldwide (tivozanib HCl, Sorafenib)

Completed
Has Results
  • Carcinoma, Renal Cell
  • Phoenix, Arizona
  • +190 more
Jan 18, 2022

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Breast Cancer Stage II Trial in Xi'an (Anlotinib)

Recruiting
  • Breast Cancer Stage II
  • Xi'an, Shannxi Province, China
    Xijing Hospital Affiliated to Air Force Military Medical Univers
Sep 25, 2022

Small Cell Lung Cancer Trial in Beijing (Chiauranib)

Recruiting
  • Small Cell Lung Cancer
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Mar 8, 2022

Sarcoma Trial in Shanghai (Apatinib monotherapy)

Recruiting
  • Sarcoma
  • Apatinib monotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022

Metastatic Sporadic Medullary Thyroid Cancer Patients and

Completed
  • Metastatic Sporadic Medullary Thyroid Cancer
    • Milano, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Sep 29, 2021

    Unresectable Locally Advanced or Metastatic Pancreatic Cancer Trial in Shanghai (surufatinib, KN046, gemcitabine)

    Not yet recruiting
    • Unresectable Locally Advanced or Metastatic Pancreatic Cancer
    • Shanghai, Shanghai, China
      Zhongshan Hospital
    Apr 16, 2023

    Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)

    Recruiting
    • Gastric Cancer
    • Jinan, Shandong, China
      Qilu hospital of Shandong univertisy
    Mar 30, 2022

    Breast Cancer, Triple-Negative Breast Cancer Trial in Guangzhou, Nanjing, Shanghai (Anti-PD-1 mAb, VEGFR2 Tyrosine Kinase

    Recruiting
    • Breast Cancer
    • Triple-Negative Breast Cancer
    • Anti-PD-1 monoclonal antibody
    • VEGFR2 Tyrosine Kinase Inhibitor
    • Guangzhou, Guangdong, China
    • +2 more
    Sep 24, 2022

    NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Department of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
    Dec 7, 2021

    Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer Trial in Australia (Pembrolizumab plus denosumab)

    Recruiting
    • Renal Cell Carcinoma, Clear Cell
    • Metastatic Kidney Cancer
    • Pembrolizumab plus denosumab
    • Albury, New South Wales, Australia
    • +15 more
    Feb 14, 2022

    Renal Carcinoma Metastatic Trial in Italy (Axitinib Oral Tablet, Avelumab)

    Recruiting
    • Renal Carcinoma Metastatic
    • Monserrato, Cagliari, Italy
    • +19 more
    Jan 5, 2021

    Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

    Not yet recruiting
    • Lung Cancer
    • +4 more
    • (no location specified)
    Sep 15, 2023

    Renal Cell Carcinoma Trial in Omaha, Cleveland, Philadelphia (Axitinib)

    Terminated
    Has Results
    • Renal Cell Carcinoma
    • Omaha, Nebraska
    • +2 more
    Jul 26, 2021

    Hepatocellular Carcinoma Trial in Shanghai (Chiauranib)

    Completed
    • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Zhongshan Hospital of Fudan University
    Jun 15, 2021

    Renal Cell Cancer Trial in Seoul (Cabometyx)

    Not yet recruiting
    • Renal Cell Cancer
    • Seoul, Korea, Republic of
      Asan Medical Center
    Jan 15, 2021

    MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

    Not yet recruiting
    • MSI-H Colorectal Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Aug 17, 2023

    Metastatic Renal Cell Carcinoma Trial in Wien, Essen (Nivolumab, Sunitinib, Pazopanib)

    Terminated
    • Metastatic Renal Cell Carcinoma
    • Wien, Austria
    • +1 more
    Sep 7, 2021

    Recurrent Glioma Trial in Zhengzhou (Apatinib)

    Recruiting
    • Recurrent Glioma
    • Zhengzhou, Henan, China
      Department of Neurosurgery, First Affiliated Hospital of Zhengzh
    Feb 5, 2021